Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - February 2013


7th Annual Improving Solubility Conference

26 Feb 2013 - 28 Feb 2013 - Philadelphia, PA, USA



Bookmark and Share


IQPC’s Improving Solubility Conference has become an annual meeting for the scientific community. This year, we will showcase the newest solubility technologies and provide the latest research from established industry leaders in order to provide you with practical, applicable knowledge to effectively improve bioavailability and drug candidate solubility.

The competition in the pharmaceutical market is at an all time high and without solid techniques to drive increased bioavailability of your products, you will be left in the dust. Learn the latest methodologies and technologies to take on this challenge and minimize the time-to-market on your drug pipeline.

Gain access to exclusive case studies on:

•    Approaches to Leverage In-Vitro Data to Hypothesize In-Vivo Data
•    Rational Formulation Design Guided by Biopharmaceutics Modeling and Automated Formulation Screening
•    Designing and Developing Super Saturation Based Drugs
•    Enhancing the In-Vivo Performance Hot-Melt Extrusion
•    Introducing Levitation Technology for the Production of Amorphous Drugs
•    Co-Crystal Development: From Mortar & Pestle to Production
•    Influence of Particle Size on the Ultraviolet Spectrum of Particulate-Containing Solutions
•    Stability Prediction for Amorphous Materials



Further information
Scientific News
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
First Made-in-Singapore Cancer Drug Enters Clinical Testing
The drug prevents cancer progression and paves the way for new advancements in cancer therapeutics.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!